Welcome to our dedicated page for Genetic Technologies news (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies stock.
Genetic Technologies Limited (GENE) delivers innovative genomic risk assessment solutions through its geneType and EasyDNA platforms. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in predictive diagnostics, strategic collaborations, and regulatory milestones.
Access official press releases covering quarterly earnings, product validations, patent approvals, and partnership announcements. Our curated feed simplifies tracking of GENE’s progress in integrating genetic insights into clinical decision-making and consumer health programs.
Discover updates about the company’s molecular testing innovations, including developments in oncology risk stratification and population health initiatives. Content spans financial disclosures, research breakthroughs, and global expansion efforts across healthcare markets.
Bookmark this page for streamlined access to verified information about Genetic Technologies’ operational developments. Check regularly for new insights into how GENE continues shaping personalized medicine through advanced DNA analysis technologies.
Genetic Technologies Limited (NASDAQ: GENE) announced significant growth in its quarterly business update for Q3 FY23, reflecting ongoing momentum in its genomics-based testing market.
Key highlights include:
- Receipt of A$4.22 million in the March quarter, with A$2.23 million from customers, a 13% increase year-on-year.
- Year-to-date customer receipts of A$6.7 million, up 45% from the prior period.
- Expansion of the geneType multi-test panel to cover nine diseases.
- Formation of a strategic alliance with QIAGEN to enhance market position.
- Introduction of the world’s first Comprehensive Breast & Ovarian Cancer Risk Test.
GTG remains focused on achieving breakeven cash flow by leveraging its multi-brand strategy and partnerships.
Genetic Technologies Limited (NASDAQ: GENE) announced a significant advancement in prostate cancer risk assessment with the publication of a study validating its geneType Prostate Cancer Risk Assessment Test. This test identifies 23% more men at high risk of prostate cancer compared to family history alone, enhancing the effectiveness of PSA screening methods. The research involved nearly 200,000 men from the UK Biobank and marks the fifth publication in the past six months on their geneType suite of tests. This development underscores GTG's commitment to improving health outcomes and reducing unnecessary medical interventions by providing a more targeted screening approach. The test is now commercially available, reflecting the ongoing scientific development in genomics-based health testing.
Genetic Technologies Limited (NASDAQ: GENE) has announced the US launch of three new disease assessments, expanding its geneType Multi-Test to include melanoma, pancreatic cancer, and atrial fibrillation. This addition raises the total number of risk assessments to nine from a single saliva sample. The updated test is now available for all ethnicities and provides risk stratification for various serious diseases, enhancing early detection and patient outcomes. According to estimates, melanoma and pancreatic cancer will see approximately 97,610 and 64,050 new cases respectively in 2023, emphasizing the importance of this testing.
Genetic Technologies Limited (NASDAQ: GENE) announced the publication of a new research paper in Cancer Prevention Research, reinforcing the efficacy of its geneType Breast Cancer Risk Assessment Test. This study, utilizing over 200,000 women from the UK Biobank, highlights geneType's superior performance over traditional models like BCRAT over a five-year period. Notably, women classified at ≥3% risk by geneType exhibited a 1.829 times higher incidence of breast cancer. This marks the second peer-reviewed publication in a month, supporting geneType’s role as a crucial risk stratification tool for the general population, and reflects the company’s commitment to clinical validation.
